Funding sources This study was supported financially by Merk-Serono S.A.
CONCISE COMMUNICATION
Comparison of Skindex-29, Dermatology Life Quality Index, Psoriasis Disability Index and Medical Outcome Study Short Form 36 in patients with mild to severe psoriasis
Article first published online: 27 MAR 2012
DOI: 10.1111/j.1365-2133.2012.10806.x
© 2012 The Authors. BJD © 2012 British Association of Dermatologists
Additional Information
How to Cite
Fernandez-Peñas, P., Jones-Caballero, M., Espallardo, O. and García-Díez, A. (2012), Comparison of Skindex-29, Dermatology Life Quality Index, Psoriasis Disability Index and Medical Outcome Study Short Form 36 in patients with mild to severe psoriasis. British Journal of Dermatology, 166: 884–887. doi: 10.1111/j.1365-2133.2012.10806.x
Conflicts of interest O.E. was an employee at Merk-Serono at the time of this study. She is no longer affiliated with the company.
Publication History
- Issue published online: 27 MAR 2012
- Article first published online: 27 MAR 2012
- Accepted manuscript online: 9 JAN 2012 03:55PM EST
- Accepted for publication 27 December 2011
- Abstract
- Article
- References
- Cited By
Summary
Background Severity assessment of patients with psoriasis is a critical issue. Classical clinical assessment has recently been combined with quality of life (QoL) scores, but several instruments are used. Moreover, studies have focused on patients with moderate to severe psoriasis.
Objectives To compare the characteristics of QoL instruments in patients with the full range of psoriasis severity attending dermatology clinics.
Methods Observational, prospective, multicentre study. Patients completed Skindex-29 (anchor) and a second instrument randomly selected from Dermatology Life Quality Index (DLQI), Psoriasis Disability Index (PDI) and Medical Outcome Study Short Form 36 (SF-36).
Results Demographic data, Psoriasis Area and Severity Index and affected body surface area were not different between the three groups. Skindex-29 showed a weak but significant correlation with clinical severity; only PDI showed similar correlation. PDI, DLQI and SF-36 showed a substantial floor effect in patients with mild to severe psoriasis. Skindex-29 showed strong correlations with the other three QoL instruments. SF-36 was more sensitive than the other instruments in detecting worse QoL in male patients.
Conclusions Skindex-29 has better sensitivity to clinical severity with minimal floor effect, and covers the main domains explored by the other three QoL instruments in patients with mild to severe psoriasis.

1365-2133/asset/olbannerleft.jpg?v=1&s=3d13800721e0d35da4d49e694f63a9d81054ca17)
1365-2133/asset/olbannerright.jpg?v=1&s=9ea9b247f2d7101244b2bef959a0874a886ec363)
